{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:10:13Z","timestamp":1791897013831,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Medical Foundation of An Qiu People\u2019s Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41429-024-00801-8","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T11:35:30Z","timestamp":1734953730000},"page":"190-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Activity of cefiderocol in combination with tetracycline analogues against carbapenem-resistant Acinetobacter baumannii"],"prefix":"10.1038","volume":"78","author":[{"given":"Yuhan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"801_CR1","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1093\/cid\/ciad094","volume":"76","author":"RK Shields","year":"2023","unstructured":"Shields RK, Paterson DL, Tamma PD. Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections. Clin Infect Dis. 2023;76:S179\u2013S93.","journal-title":"Clin Infect Dis"},{"key":"801_CR2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41429-019-0188-6","volume":"72","author":"HS Ozger","year":"2019","unstructured":"Ozger HS, et al. In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates. J Antibiot (Tokyo). 2019;72:600\u20134.","journal-title":"J Antibiot (Tokyo)"},{"key":"801_CR3","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1093\/ofid\/ofy293","volume":"6","author":"AC Gales","year":"2019","unstructured":"Gales AC, et al. Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY antimicrobial surveillance program (1997\u20132016). Open Forum Infect Dis. 2019;6:S34\u2013S46.","journal-title":"Open Forum Infect Dis"},{"key":"801_CR4","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41429-023-00653-8","volume":"76","author":"P Gaibani","year":"2023","unstructured":"Gaibani P, Lazzarotto T, Viale P, Ambretti S. In vitro activity of cefiderocol in combination with new \u03b2-lactam\/\u03b2-lactamase inhibitor combinations (\u03b2L-\u03b2LICs) against multidrug resistant KPC-producing Klebsiella pneumoniae. J Antibiot (Tokyo). 2023;76:682\u20138.","journal-title":"J Antibiot (Tokyo)"},{"key":"801_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.896971","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang C, Yang D, Wang Y, Ni W. Cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: a systematic review of currently available evidence. Front Pharm. 2022;13:896971.","journal-title":"Front Pharm"},{"key":"801_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40121-022-00597-w","volume":"11","author":"C Bartal","year":"2022","unstructured":"Bartal C, Rolston KVI, Nesher L. Carbapenem-resistant Acinetobacter baumannii: colonization, infection and current treatment options. Infect Dis Ther. 2022;11:683\u201394.","journal-title":"Infect Dis Ther"},{"key":"801_CR7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/antibiotics11101298","volume":"11","author":"MS Deolankar","year":"2022","unstructured":"Deolankar MS, et al. Evaluating the efficacy of eravacycline and omadacycline against extensively drug-resistant Acinetobacter baumannii patient isolates. Antibiotics (Basel). 2022;11:1298.","journal-title":"Antibiotics (Basel)"},{"key":"801_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, et al. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75:187\u2013212.","journal-title":"Clin Infect Dis"},{"key":"801_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/CMR.05041-11","volume":"25","author":"PD Tamma","year":"2012","unstructured":"Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25:450\u201370.","journal-title":"Clin Microbiol Rev"},{"key":"801_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01968-17","volume":"62","author":"MA Hackel","year":"2018","unstructured":"Hackel MA, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62:e01968-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"801_CR11","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, (Twenty-sixth Informational Supplement [M100-S33]). Clinical and Laboratory Standards Institute. Wayne: PA, USA; 2023."},{"key":"801_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ja.2016.93","volume":"70","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Li P, Yin Y, Li F, Zhang Q. In vitro activity of tigecycline in combination with rifampin, doripenem or ceftazidime against carbapenem-resistant Klebsiella pneumoniae bloodstream isolates. J Antibiot (Tokyo). 2017;70:193\u20135.","journal-title":"J Antibiot (Tokyo)"},{"key":"801_CR13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s10096-022-04503-7","volume":"41","author":"W Ni","year":"2022","unstructured":"Ni W, et al. In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2022;41:1451\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"801_CR14","doi-asserted-by":"crossref","unstructured":"Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1.","DOI":"10.1093\/jac\/dkg301"},{"key":"801_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00542-22","volume":"10","author":"T Abbey","year":"2022","unstructured":"Abbey T, Vialichka A, Jurkovic M, Biagi M, Wenzler E. Activity of omadacycline alone and in combination against carbapenem-nonsusceptible Acinetobacter baumannii with varying minocycline susceptibility. Microbiol Spectr. 2022;10:e0054222.","journal-title":"Microbiol Spectr"},{"key":"801_CR16","first-page":"2164","volume":"75","author":"I Galani","year":"2020","unstructured":"Galani I, et al. In vitro activity of ceftolozane\/tazobactam alone and in combination with amikacin against MDR\/XDR Pseudomonas aeruginosa isolates from Greece. J Antimicrob Chemother. 2020;75:2164\u201372.","journal-title":"J Antimicrob Chemother."},{"key":"801_CR17","doi-asserted-by":"publisher","first-page":"e01022","DOI":"10.1128\/AAC.01022-17","volume":"61","author":"ML Monogue","year":"2017","unstructured":"Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61:e01022\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"801_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331.","journal-title":"J Basic Clin Pharm"},{"key":"801_CR19","doi-asserted-by":"publisher","first-page":"e00997","DOI":"10.1128\/AAC.00997-19","volume":"63","author":"TE Asempa","year":"2019","unstructured":"Asempa TE, Nicolau DP, Kuti JL. In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63:e00997\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"801_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226\u201340.","journal-title":"Lancet Infect Dis"},{"key":"801_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","volume":"30","author":"S Karakonstantis","year":"2024","unstructured":"Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect. 2024;30:178\u201388.","journal-title":"Clin Microbiol Infect"},{"key":"801_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2165\/00003495-200565100-00002","volume":"65","author":"E Rubinstein","year":"2005","unstructured":"Rubinstein E, Vaughan D. Tigecycline: a novel glycylcycline. Drugs. 2005;65:1317\u201336.","journal-title":"Drugs"},{"key":"801_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/antibiotics13030261","volume":"13","author":"P Rafailidis","year":"2024","unstructured":"Rafailidis P, Panagopoulos P, Koutserimpas C, Samonis G. Current therapeutic approaches for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii infections. Antibiotics (Basel). 2024;13:261.","journal-title":"Antibiotics (Basel)"},{"key":"801_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","volume":"80","author":"GG Zhanel","year":"2020","unstructured":"Zhanel GG, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent. Drugs. 2020;80:285\u2013313.","journal-title":"Drugs"},{"key":"801_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2024.2351552","volume":"22","author":"PY Huang","year":"2024","unstructured":"Huang PY, Hsu CK, Tang HJ, Lai CC. Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications. Expert Rev Anti Infect Ther. 2024;22:387\u201398.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"801_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","volume":"51","author":"H Seifert","year":"2018","unstructured":"Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018;51:62\u20134.","journal-title":"Int J Antimicrob Agents"},{"key":"801_CR27","first-page":"e01110","volume":"63","author":"B Isler","year":"2018","unstructured":"Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2018;63:e01110\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"801_CR28","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1089\/mdr.2016.0279","volume":"23","author":"J Li","year":"2017","unstructured":"Li J, Yang X, Chen L, Duan X, Jiang Z. In vitro activity of various antibiotics in combination with tigecycline against Acinetobacter baumannii: a systematic review and meta-analysis. Micro Drug Resist. 2017;23:982\u201393.","journal-title":"Micro Drug Resist"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00801-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00801-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00801-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T23:03:04Z","timestamp":1740610984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00801-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1038\/s41429-024-00801-8","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}